Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092459869> ?p ?o ?g. }
- W2092459869 endingPage "102" @default.
- W2092459869 startingPage "91" @default.
- W2092459869 abstract "Somatostatin (SS) and dopamine (DA) receptors are widely expressed in neuroendocrine tumours that cause Cushing's Syndrome (CS). Increasing knowledge of specific subtype expression within these tumours and the ability to target these receptor subtypes with high-affinity compounds, has driven the search for new SS- or DA-based medical therapies for the various forms of CS. In Cushing's disease, corticotroph adenomas mainly express dopamine receptor subtype 2 (D(2)) and somatostatin receptor subtype 5 (sst(5)), whereas sst(2) is expressed at lower levels. Activation of these receptors can inhibit ACTH-release in primary cultured corticotroph adenomas and compounds that target either sst(5) (pasireotide, or SOM230) or D(2) (cabergoline) have shown significant efficacy in subsets of patients in recent clinical studies. Combination therapy, either by administration of both types of compounds separately or by treatment with novel somatostatin-dopamine chimeric molecules (e.g. BIM-23A760), appears to be a promising approach in this respect. In selected cases of Ectopic ACTH-producing Syndrome (EAS), the sst(2)-preferring compound octreotide is able to reduce cortisol levels effectively. A recent study showed that D(2) receptors are also significantly expressed in the majority of EAS and that cabergoline may decrease cortisol levels in subsets of these patients. In both normal adrenal tissue as well as in adrenal adenomas and carcinomas that cause CS, sst and DA receptor expression has been demonstrated. Although selected cases of adrenal CS may benefit from sst or DA-targeted treatment, its total contribution to the treatment of these patients is likely to be low as surgery is effective in most cases." @default.
- W2092459869 created "2016-06-24" @default.
- W2092459869 creator A5006066076 @default.
- W2092459869 creator A5032332063 @default.
- W2092459869 creator A5040710891 @default.
- W2092459869 creator A5053534170 @default.
- W2092459869 date "2008-07-19" @default.
- W2092459869 modified "2023-10-17" @default.
- W2092459869 title "Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome" @default.
- W2092459869 cites W1531191121 @default.
- W2092459869 cites W1536517901 @default.
- W2092459869 cites W1925492557 @default.
- W2092459869 cites W1965731442 @default.
- W2092459869 cites W1966184376 @default.
- W2092459869 cites W1967619819 @default.
- W2092459869 cites W1969016961 @default.
- W2092459869 cites W1969144523 @default.
- W2092459869 cites W1969594608 @default.
- W2092459869 cites W1969784954 @default.
- W2092459869 cites W1970108520 @default.
- W2092459869 cites W1971802636 @default.
- W2092459869 cites W1979625935 @default.
- W2092459869 cites W1984025513 @default.
- W2092459869 cites W1984313624 @default.
- W2092459869 cites W1987947990 @default.
- W2092459869 cites W1988395319 @default.
- W2092459869 cites W1993984263 @default.
- W2092459869 cites W1995919135 @default.
- W2092459869 cites W1996774505 @default.
- W2092459869 cites W1998309516 @default.
- W2092459869 cites W1998673854 @default.
- W2092459869 cites W1998767852 @default.
- W2092459869 cites W2002389632 @default.
- W2092459869 cites W2002475824 @default.
- W2092459869 cites W2004454944 @default.
- W2092459869 cites W2005518939 @default.
- W2092459869 cites W2010512930 @default.
- W2092459869 cites W2010703529 @default.
- W2092459869 cites W2011055073 @default.
- W2092459869 cites W2012451298 @default.
- W2092459869 cites W2015740453 @default.
- W2092459869 cites W2016753202 @default.
- W2092459869 cites W2017502291 @default.
- W2092459869 cites W2028805801 @default.
- W2092459869 cites W2031046770 @default.
- W2092459869 cites W2033505874 @default.
- W2092459869 cites W2036086804 @default.
- W2092459869 cites W2039064285 @default.
- W2092459869 cites W2040677803 @default.
- W2092459869 cites W2045645101 @default.
- W2092459869 cites W2052944345 @default.
- W2092459869 cites W2055894261 @default.
- W2092459869 cites W2057136277 @default.
- W2092459869 cites W2057835402 @default.
- W2092459869 cites W2058417098 @default.
- W2092459869 cites W2059027605 @default.
- W2092459869 cites W2061702213 @default.
- W2092459869 cites W2062945264 @default.
- W2092459869 cites W2066646119 @default.
- W2092459869 cites W2067084033 @default.
- W2092459869 cites W2067202852 @default.
- W2092459869 cites W2069822063 @default.
- W2092459869 cites W2071310612 @default.
- W2092459869 cites W2074460096 @default.
- W2092459869 cites W2075317954 @default.
- W2092459869 cites W2075366904 @default.
- W2092459869 cites W2077451709 @default.
- W2092459869 cites W2077698836 @default.
- W2092459869 cites W2078910383 @default.
- W2092459869 cites W2079846716 @default.
- W2092459869 cites W2080232093 @default.
- W2092459869 cites W2082819145 @default.
- W2092459869 cites W2087723189 @default.
- W2092459869 cites W2093465935 @default.
- W2092459869 cites W2102046813 @default.
- W2092459869 cites W2102710453 @default.
- W2092459869 cites W2103233430 @default.
- W2092459869 cites W2111664153 @default.
- W2092459869 cites W2112309011 @default.
- W2092459869 cites W2116182759 @default.
- W2092459869 cites W2118708995 @default.
- W2092459869 cites W2123601063 @default.
- W2092459869 cites W2129133209 @default.
- W2092459869 cites W2130956345 @default.
- W2092459869 cites W2131231109 @default.
- W2092459869 cites W2132647852 @default.
- W2092459869 cites W2133608824 @default.
- W2092459869 cites W2138241644 @default.
- W2092459869 cites W2140219691 @default.
- W2092459869 cites W2140741951 @default.
- W2092459869 cites W2142624660 @default.
- W2092459869 cites W2145493248 @default.
- W2092459869 cites W2147613968 @default.
- W2092459869 cites W2147800245 @default.
- W2092459869 cites W2157490051 @default.
- W2092459869 cites W2159306530 @default.
- W2092459869 cites W2160213256 @default.
- W2092459869 cites W2162762231 @default.